Company intelligence / Profile preview

Xcyte Therapies

Seattle, Washington, USAxcytetherapies.com ↗

Ownership: Private
Development stage: Other

Overview

Xcyte Therapies developed ex vivo cellular therapies using its proprietary Xcellerate Technology to activate and expand autologous T cells for treating cancer, infectious diseases, and immunodeficiencies. The company’s lead programs were discontinued after regulatory setbacks. Its core technology was sold to Invitrogen in 2005 for $5 million. The remaining business merged with Cyclacel Pharmaceuticals via a reverse merger in late 2005, ceasing independent operations.

Therapeutic areas: Infectious DiseasesDermatologyImmunologyOncology
Modalities: Cell therapyActivated T cells
Industry: Biotech

Partnerships

Genetics Institute/BioPharma licensing agreements for ex vivo activation/expansion patents.Technology sale to Invitrogen.

Beyond the preview

Go deeper on Xcyte Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcyte Therapies.

Explore the full profile